BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS Russian patent published in 2018 - IPC G01N33/53 G01N33/574 

FIELD: biotechnology; medicine.

SUBSTANCE: disclosed are methods of predicting the response of a human subject having, suspected of having, or at risk of developing, an endometrial cancer to a therapy comprising lenvatinib or a pharmaceutically acceptable salt (versions) thereof. Method comprises assaying a biological sample obtained from the human subject and determining the concentration of angiopoietin 2 (Ang2) protein in the biological sample. Concentration of Ang2 is compared to a control, where the control is a predetermined threshold value in the range of 1866.5 to 6024.5 pg/ml. Method then comprises identifying the human subject having a low concentration of Ang2 protein in the biological sample as likely to respond to the therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof. At a high concentration of the Ang2 protein in the biological sample, a human subject is identified as not likely to respond to therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof.

EFFECT: invention allows the identification, stratification and / or selection of patients with endometrial cancer that can benefit from treatment with lenvatinib or a pharmaceutically acceptable salt thereof.

17 cl, 6 dwg, 14 tbl, 2 ex